TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.99 USD | +1.23% |
|
-5.22% | -18.09% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 18 | Sector Update: Health Care | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the TG Therapeutics Seco...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.99
USD
Average target price
29.75
USD
Spread / Average Target
+112.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.09% | 2B | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- Transcript : TG Therapeutics, Inc., Q2 2020 Earnings Call, Aug 10, 2020
